Background
Extraovarian primary peritoneal carcinoma (EOPPC) is a rare malignant epithelial tumor with an age-adjusted incidence rate of 6.78 per million [1] , which arises from the peritoneal lining with minimal or no ovarian involvement.
In 1959, Swerdlow reported a peritoneal mass in a 27-year-old woman with uninvolved ovaries and fallopian tubes, histologically similar to papillary serous carcinoma of the ovary, and named it "mesothelioma of the pelvic peritoneum" [2] . In 1977, Kannerstein et al. called for distinguishing the disease from malignant mesothelioma, which does not share the epidemiologic and biologic feature of primary peritoneal carcinoma [3] .
EOPPC is a diagnosis of exclusion with the absence of other identifiable primary sites and after surgical assessment and consideration of the histological report to evaluate the extent of ovarian invasion.
In 1993, the Gynecologic Oncology Group defined criteria to distinguish EOPPC from serous adenocarcinoma of the ovary: I. Both ovaries must be either normal in size or enlarged by a benign process; II. The involvement in extraovarian sites must be greater than the involvement on the surface of either ovary; III. Microscopically, the ovarian component must be either nonexistent, have no signs of cortical invasion, or have a tumor size less than 5 mm 2 within ovarian substance with or without surface disease; IV. The histological and cytological characteristics of the tumor must be predominantly of the serous type that is similar to ovarian serous cancer of any grade [4] .
However, EOPPC does not have a separate staging system, making the application of the FIGO staging system necessary. Due to the peritoneal involvement, all patients are at least considered stage III or IV. Metastasis usually occurs transperitoneally, but lymphatic spread is frequent (63-73%) [5, 6] .
The peritoneum shares a common embryonal heritage with ovarian tissue, deriving from coelomic epithelium just as the Müllerian ductal system does [7] . The retained potential for Müllerian differentiation may explain the development of primary malignant entities similar to epithelial ovarian cancer along the peritoneal lining. Despite the biological proximity of the tissues, the final answer to the pathological origin of the disease remains to be found.
Differentiation to peritoneal carcinomatosis from metastatic gastrointestinal cancers and advanced-stage epithelial ovarian cancer is important for planning the surgical approach.
Differential diagnosis includes metastatic peritoneal carcinomatosis, malignant mesothelioma, peritoneal psammocarcinoma, and endosalpingiosis, as well as other benign or borderline diseases. Malignant mesothelioma is linked to a history of asbestos exposure and occurs more frequently in males.
[8] Distinction from primary peritoneal carcinoma can be supported by immunohistochemistry with malignant mesothelioma staining positive for h-CD an Calretinin and virtually never for mucin [9] . Estrogen receptor (ER) positivity was found to be positive in 86% of women with EOPPC and 88% of women with epithelial ovarian cancer with no ER-expression in malignant mesothelioma.
Survival in EOPPC patients remains poor, with Eltabbakh et al. reporting a median overall survival of 23.5 months [10] , and 5 year-survival-rates in the literature ranging from 0% to 26.5% [9] .
Case Report
A 66-year-old woman, known to have dyslipidemia and osteoporosis, presented for abdominal distension with constipation of 3 days, while still passing flatus. She further complained of mild postprandial epigastric pain, but denied nausea, vomiting, and fever. Concerning her past surgical history, the patient had an open cholecystectomy 20 years prior to presentation.
The physical exam revealed positive bowel sounds over all 4 quadrants, with a soft, non-tender abdomen. Distension and dullness to percussion were noted.
The laboratory results on admission were inconspicuous, and a CT scan of the abdomen was scheduled to further investigate the complaints (Figures 1, 2) , which revealed slight thickening of small bowel loops with no visible air fluid level. Moderate amounts of peritoneal fluid were found in the perihepatic and perisplenic space as well as in the pouch of Douglas. There was infiltration of the mesenteric fat, with diffuse enlargement of the omentum. A subsequent PET/CT scan with application of 18 F-FDG evoked the image of an intensely tracer-avid peritoneal carcinomatosis without signs of another identifiable primary disease (Figure 3 ).
An exploratory laparoscopy confirmed diffuse carcinomatosis in the omentum and the coloparietal region bilaterally, as well as surrounding small bowel loops, the transverse and sigmoid colon, and the rectum. A bilateral oophorectomy was performed and 2 biopsies from the thickened peritoneum were taken. The histomorphological features from the pathology examination concluded peritoneal serous carcinoma with uninvolved ovaries (Figure 4) . The patient completed 6 cycles of systemic chemotherapy using Carboplatin combined with Paclitaxel and Bevacizumab. A repeat CT scan showed carcinomatosis, and a decrease in CA-125 to 52 µ/L was noted. The patient was scheduled for debulking surgery after radiography, which is a marker of clinical response.
Exploration of the abdominal cavity revealed completely resectable disease, with flat disease (<0.5 mm) in PCI regions 0, 1, 2, 6, and 12 (PCI 6). The patient received a radical hysterectomy, followed by resection of the omentum and the appendix. A peritonectomy over the right Gerota's fascia and stripping of the right hemi-diaphragm in toto were performed. Furthermore, mesocolic and small bowel nodules were treated by meticulous resection and ablation, respectively. No complications arose during the procedure, which resulted in no residual visual disease. The postoperative course was uneventful and the patient was discharged on the 5 th postoperative day.
The pathology report confirmed the diagnosis of well-differentiated peritoneal papillary serous carcinoma (G1, pT3A). Lymphatic vascular invasion was noted, with few intralymphatic tumor emboli.
The patient presented 2 weeks after the debulking surgery with back and abdominal pain, and a CT scan revealed bibasilar atelectatic changes of the lung parenchyma, with a thick atelectatic band on the left. Symptoms were relieved by analgetic treatment and the patient was discharged shortly thereafter.
Two months after debulking surgery, no signs of relapse were noted.
After 1-year follow-up, abdomen and pelvis CT scans were normal, with no carcinomatosis or symptoms. We used CT scanning for the diagnosis, which is more sensitive and specific than ultrasound.
Discussion
Since EOPPC has to be distinguished from differential malignant diseases, surgical findings and histopathological examination are obligatory for diagnosis. The clinical presentation may consist of nonspecific symptoms like abdominal pain, distension, and constipation, as in our patient. Other symptoms may include gastrointestinal symptoms (e.g., nausea/vomiting and dyspepsia), change in weight, and abdominal or pelvic masses, overlapping the symptomatic spectrum of ovarian cancer and thus rendering it indistinguishable without further workup.
Radiological imaging is a valuable tool for guiding surgical management. Even without final differentiation between malignancies, the use of PET/CT employing 18 F-FDG has been well established for assessing the biological activity and presence of a suspicious mass [11] .
Remarkable elevation of serum tumor markers such as CA-125 can be of use in identifying suspected malignancy and has been found to be correlated with epithelial ovarian cancer as well as, in EOPPC patients, with extent and stage of disease [12] . It is a valuable tool to use in monitoring disease progression, response to treatment, and relapse, as shown in this patient.
(Neo-) adjuvant chemotherapy agents used in ovarian cancer can be applied in EOPPC due to molecular similarities. Response rates of 79% in EOPPC patients to first-line platinum-based chemotherapy are comparable [13, 14] .
Due to the importance of optimal primary cytoreduction with residual masses <1.0 cm [15] , an open approach is deemed inevitable. Additional hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered to further improve prognosis and response rates of residual disease. Complete cytoreductive surgery is achieved in 89% of cases and is therefore comparable to epithelial ovarian cancer patients [16] .
Lesions are serous well-differentiated in >90% of patients [10] , as is our case.
No distinct risk factors for the development of EOPPC have been identified, excepting BRCA 1 and 2 germline mutations [17] . Menczer et al. reported similar frequency distributions of BRCA 1/2 mutation for both ovarian and primary peritoneal carcinoma, further indicating a shared molecular pathogenesis [18] . Carrier status was associated with earlier onset and multifocal disease.
Conclusions
EOPPC may be misdiagnosed as epithelial ovarian cancer, but should be considered in patients with peritoneal carcinomatosis, normal-sized ovaries, and no identifiable primary lesion. Still, to further improve survival, optimal cytoreductive surgery is essential and should be a priority in disease management.
